Evidence map›Paper›PMID 26922433›Full record

ReviewCurrent allergy and asthma reports2016

The Heterogeneity of Oral Immunotherapy Clinical Trials: Implications and Future Directions.

Christina S K Yee, Rima Rachid

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current allergy and asthma reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 2 pooled it
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. The current state of food allergy therapeutics.Human vaccines & immunotherapeutics · 2017
    Review
  11. Emerging Approaches to Food Desensitization in Children.Current allergy and asthma reports · 2017
    Review
  12. Review
  13. Update on Potential Therapies for IgE-Mediated Food Allergy.Current allergy and asthma reports · 2017
    Review
  14. Deciphering the black box of food allergy mechanisms.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2017
    Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Christina S K YeeDivision of Allergy and Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
Rima RachidDivision of Allergy and Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA. Rima.Rachid@childrens.harvard.edu.
Boston Children's Hospital · USHarvard University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Food allergy is a potentially life-threatening disease which affects up to 8% of children and 2-3% of adults. Increasing food allergy prevalence poses a major public health concern. Induction of desensitization to food allergens through oral immunotherapy (OIT) is an expanding area of study encompassing peanut, egg, milk, and other food allergens. OIT consists of administering incremental doses of food allergen to food-allergic patients, to induce a state of desensitization. Safety, tolerability, and efficacy all remain ongoing concerns. Clinical trials for oral immunotherapy have encompassed many variations, including differences in dosage sizes and frequency, duration of build-up, type of allergen used, patient characteristics, and adjuvant therapies. Consequently, studies have also shown variation in rates of adverse effects, and successful desensitization. Here, we provide an overview of the key studies and discuss the implications of this heterogeneity. While desensitization is successful in the majority of patients, only a minority appear to develop sustained unresponsiveness even after years of therapy. Much larger and longitudinal studies using more homogenous protocols are needed in order to evaluate the clinical applicability of OIT, its long-term effectiveness, and effect on quality of life. The role of adjunctive therapies, including omalizumab and probiotics, requires further evaluation.

Indexed as

Administration, OralAllergensClinical Trials as TopicDesensitization, ImmunologicFood HypersensitivityHumansOmalizumabAllergensOmalizumabDesensitizationFood allergyOral immunotherapySustained unresponsiveness

Identifiers

PMID26922433
OpenAlexW2289347954

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.